Novaliq is an independent private equity financed company. In five funding rounds the company successfully aquired a total capital sum of 27.1 Mio. Euros. The principal shareholder of the company is dievini Hopp BioTech Holding GmbH & Co. KG.
With its solid clinical and ready to market product portfolio, Novaliq provides a unique investment opportunity.
For further information on investment opportunities please contact us by Email: info[at]novaliq.de